La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Biomea Fusion a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Biomea Fusion..

Biomea Fusion (NASDAQ:BMEA) Azioni, Catena delle Opzioni

BIOMEA FUSION INC

Biomea Fusion

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Biomea Fusion Inc

Press Releases

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

News

General

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Management

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Earnings

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Health Care

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Financing

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

BMEA

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Entera Bio

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

EXoZymes

TuHURA Biosciences

Immix Biopharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Metagenomi

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

OKYO Pharma

Ovid Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

AVITA Medical

Sutro Biopharma

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Comments

Biomea Fusion

Biomea Fusion (BMEA) Opzioni

Biomea Fusion (NASDAQ:BMEA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO